Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Research Article

    Therapeutic Effect and Possible Herb Drug Interactions of Ginger (Zingiber officinale Roscoe, Zingiberaceae) Crude Extract with Glibenclamide and Insulin

    wadmin1By wadmin1January 1, 2012Updated:August 6, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Ihsan L. Al-Omaria, Fatma U. Afifib and Abdulazim S. Salhaba.

    aDepartment of Pharmacology, Faculty of Medicine, University of Jordan, Amman, Jordan.

    bDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, University of Jordan, Amman, Jordan.

    Pharmacognosy Communications,2012,2,12-20
    DOI:10.5530/pc.2012.1.4
    Published:january 2012
    Type: Research Article

    ABSTRACT

    Background: Zingiber officinale aqueous extracts have traditionally been used by diabetic patients in Jordan. Objective: The present study aims to evaluate the hypoglycemic and antihyperglycemic effects of ginger crude extract (GCE) in normoglycemic- and streptozotocin (STZ)- diabetic- rats and to assess the possible herb-drug interactions with glibenclamide and insulin. Materials and Methods: Oral glucose tolerance test (OGTT) was determined for GCE at concentrations 25, 50 and 100 mg/kg body weight (BW). GCE was administered to normoglycemicrats as a single dose (1 day) and as a daily dose for 1 week. STZ diabetic rats were treated with the same GCE concentrations (25, 50 and 100 mg/kg BW) together with glibenclamide (5 mg/kg BW) or insulin (1.2 IU/kg BW). Results: Single administration of GCE showed a significant decrease in blood glucose level (BGL) in normoglycemic rats at 1 and 2 h (50 mg/kg BW; p<0.001) while one week administration of GCE did not improve BGL. In STZ- diabetic rats GCE (25 and 50 mg/kg BW) decreased non-fasting BGL (N-FBGL) significantly (p<0.001) at 1.5, 2.5, 3.5 and 4.5 h. The combinations of Glibenclamide (5 mg/kg BW) and GCE at doses (25 or 50 mg/kg BW) exhibited after 4.5 h a significantly reduction in the N-FBGL 26.3% (p<0.001) and 25.1% (p<0.01) respectively; while glibenclamide alone exhibited 7.9% reduction. Also co-administration of GCE (50 mg/kg BW) with insulin caused a significant reduction in the N-FBGL at 2.5 (p<0.001) and 3.5 h (p<0.01) compared to insulin alone. Conclusions: The observed interaction of ginger with glibenclamide and insulin appears to be promising in reducing blood glucose levels and needs further evaluation.

    Key Words:Diabetes, ginger, herb–drug interactions, OGTT, STZ- diabetic rats.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up